Used as a potent inhibitor of dipeptidyl peptidase-4 (DPP-4), this compound is developed for the treatment of type 2 diabetes. It helps regulate blood glucose levels by enhancing the activity of incretin hormones, which stimulate insulin release in a glucose-dependent manner. Due to its selective binding and long-lasting effect, it offers improved glycemic control with a low risk of hypoglycemia. The compound’s structure supports high oral bioavailability and metabolic stability, making it suitable for once-daily dosing in antidiabetic therapy.